Morgan Stanley’s Harpoon Therapeutics, Inc. Common Stock HARP Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q1 | – | Sell |
-504
| Closed | -$5.73K | – | 8137 |
|
|
2023
Q4 | $5.73K | Buy |
504
+33
| +7% | +$259 | ﹤0.01% | 6976 |
|
|
2023
Q3 | $1.9K | Sell |
471
-102
| -18% | -$756 | ﹤0.01% | 7145 |
|
|
2023
Q2 | $4.07K | Buy |
573
+201
| +54% | +$1.39K | ﹤0.01% | 7033 |
|
|
2023
Q1 | $2.77K | Buy |
372
+78
| +27% | +$656 | ﹤0.01% | 7179 |
|
|
2022
Q4 | $2.13K | Sell |
294
-1,102
| -79% | -$9.28K | ﹤0.01% | 7357 |
|
|
2022
Q3 | $14K | Sell |
1,396
-1,787
| -56% | -$33.4K | ﹤0.01% | 6962 |
|
|
2022
Q2 | $60K | Buy |
3,183
+1,288
| +68% | +$33.4K | ﹤0.01% | 6531 |
|
|
2022
Q1 | $94K | Buy |
1,895
+612
| +48% | +$31.7K | ﹤0.01% | 6355 |
|
|
2021
Q4 | $97K | Sell |
1,283
-6,093
| -83% | -$416K | ﹤0.01% | 6459 |
|
|
2021
Q3 | $583K | Sell |
7,376
-13,923
| -65% | -$1.4M | ﹤0.01% | 5399 |
|
|
2021
Q2 | $2.96M | Buy |
21,299
+21,134
| +12,808% | +$4.03M | ﹤0.01% | 4309 |
|
|
2021
Q1 | $34K | Sell |
165
-1,246
| -88% | -$250K | ﹤0.01% | 6535 |
|
|
2020
Q4 | $234K | Buy |
1,411
+1,151
| +443% | +$178K | ﹤0.01% | 5515 |
|
|
2020
Q3 | $44K | Sell |
260
-1,684
| -87% | -$243K | ﹤0.01% | 5762 |
|
|
2020
Q2 | $323K | Buy |
1,944
+599
| +45% | +$93.4K | ﹤0.01% | 4832 |
|
|
2020
Q1 | $156K | Sell |
1,345
-700
| -34% | -$98.4K | ﹤0.01% | 4979 |
|
|
2019
Q4 | $303K | Buy |
2,045
+1,412
| +223% | +$214K | ﹤0.01% | 5212 |
|
|
2019
Q3 | $86K | Buy |
633
+552
| +681% | +$77.6K | ﹤0.01% | 5495 |
|
|
2019
Q2 | $10K | Buy |
81
+27
| +50% | +$3.14K | ﹤0.01% | 6142 |
|
|
2019
Q1 | $5K | Buy |
+54
| New | +$7.1K | ﹤0.01% | 6336 |
|
Morgan Stanley's HARP Position: Q1 2024 in Review
Morgan Stanley sold out of Harpoon Therapeutics, Inc. Common Stock (HARP) in Q1 2024, closing a stake of 504 shares — an estimated $5.73K sold.
Morgan Stanley first reported a position in HARP in Q1 2019 and held it in 20 quarters. The position peaked at $2.96M in Q2 2021. 0 funds tracked by Wall St. Rank hold HARP as of Q1 2024.
- Morgan Stanley reported no remaining Harpoon Therapeutics, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
- Morgan Stanley sold 504 Harpoon Therapeutics, Inc. Common Stock shares in Q1 2024, an estimated $5.73K.
- Morgan Stanley first reported a position in Harpoon Therapeutics, Inc. Common Stock in Q1 2019 and held it in 20 quarters.
- Morgan Stanley's Harpoon Therapeutics, Inc. Common Stock position peaked at $2.96M in Q2 2021.
- 0 funds tracked by Wall St. Rank held Harpoon Therapeutics, Inc. Common Stock as of Q1 2024.
Based on Morgan Stanley's 13F filing for Q1 2024, filed 15 May 2024.